Conference data: Four-year data demonstrate durable viral suppression with Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate) in treatment-naïve adults with HIV

Data from open-label extensions of two Phase 3 studies(n=235/237 for study 1489, n=241/243 for study 1490) demonstrated that >98% of subjects maintained an undetectable viral load (HIV-1 RNA <50 copies/mL) through four years of follow-up with no treatment-emergent resistance.

Source:

Biospace Inc.